ORBENIN-DC- cloxacillin benzathine suspension

Orbenin-DC by

Drug Labeling and Warnings

Orbenin-DC by is a Animal medication manufactured, distributed, or labeled by Merck Sharp & Dohme Corp.. Drug facts, warnings, and ingredients follow.

Drug Details [pdf]

  • INDICATIONS & USAGE

    INDICATIONS: Orbenin-DC is indicated in the treatment and prophylaxis of bovine mastitis in nonlactating cows due to Staphylococcus aureus and Streptococcus agalactiae.

  • CONTRAINDICATIONS

    CONTRAINDICATIONS: Because benzathine cloxacillin is relatively insoluble, Orbenin-DC's activity will be prolonged. Therefore, Orbenin-DC should not be used for the occasional cow which may have a dry period of less than 4 weeks. This precaution will avoid residues in the milk following removal of the colostrum.

  • WARNINGS

    WARNINGS: For use in dry cows only. Do not use within 4 weeks (28 days) of calving. Treated animals must not be slaughtered for food purposes within 4 weeks (28 days) of treatment.

  • PRECAUTIONS

    PRECAUTION: Because it is a derivative of 6-amino-penicillanic acid, Orbenin-DC has the potential for producing allergic reactions. Such reactions are rare; however, should they occur, the subject should be treated with the usual agents (antihistamines, pressor amines).

  • DOSAGE & ADMINISTRATION

    DOSAGE AND ADMINISTRATION: At the last milking of lactation, milk the cow out normally. Clean and disinfect the teats with alcohol swabs provided in the carton, and infuse 1 syringe of Orbenin-DC, which has been warmed to room temperature, into each quarter. Do not milk out. The cow may be milked as usual when she calves.

    The extent of subclinical and latent mastitis in a herd is frequently greater than suspected. In untreated herds a significant buildup of subclinical mastitis may occur during the dry period, which results in clinical severity after a few lactations. The adverse influence of subclinical mastitis on milk yield, the risk of cross-infection, and the chance of clinical mastitis flare-up make it necessary to treat the matter as a herd problem. Clinical studies have proven the value of treating all the cows in heavily infected herds as they are dried off. When the herd infection has been reduced, it may be desirable to be more selective in treating infected quarters.

    Each carton contains 12 alcohol swabs to facilitate proper cleaning and disinfecting of the teat orifice.

  • HOW SUPPLIED

    HOW SUPPLIED: Orbenin-DC is supplied in cartons of 12 single-dose syringes with 12 alcohol swabs. Each disposable syringe contains 500 mg of cloxacillin as the benzathine salt in 7.5 g of suitable base.

    Do Not Store Above 24°C (75°F)

  • SPL UNCLASSIFIED SECTION

    Orbenin-DC® is a trademark owned by and used under license from SmithKline Beecham.

    NADA #55-069, Approved by FDA

    Manufactured by:
    G.C. Hanford Mfg. Co.
    Syracuse, NY 13201
    image

    Copyright © 2003, Schering-Plough Animal Health Corp.,
    Union, NJ 07083. All rights reserved.
    10/03
    B-27865909

    INS15480 01
    Printed in USA

  • PRINCIPAL DISPLAY PANEL - 12 Syringe Carton

    Orbenin-DC®
    (benzathine cloxacillin)

    DRY COW

    short tip

    Intramammary Infusion

    LONG-ACTING FORMULA

    Caution: Federal law restricts this drug to use by or
    on the order of a licensed veterinarian.

    12 single-dose (7.5 g),
    disposable syringes

    NADA #55-069, Approved by FDA

    Schering-Plough Animal Health Corp.

    PRINCIPAL DISPLAY PANEL - 12 Syringe Carton
  • INGREDIENTS AND APPEARANCE
    ORBENIN-DC 
    cloxacillin benzathine suspension
    Product Information
    Product TypePRESCRIPTION ANIMAL DRUGItem Code (Source)NDC: 0061-8134
    Route of AdministrationINTRAMAMMARY
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    cloxacillin benzathine (UNII: AC79L7PV2G) (cloxacillin - UNII:O6X5QGC2VB) cloxacillin500 mg  in 7.5 mL
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 0061-8134-0112 in 1 CARTON
    17.5 mL in 1 SYRINGE
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    NADANADA05506903/11/1975
    Labeler - Merck Sharp & Dohme Corp. (001317601)

  • Trademark Results [Orbenin-DC]

    Mark Image

    Registration | Serial
    Company
    Trademark
    Application Date
    ORBENIN-DC
    ORBENIN-DC
    72461483 0982464 Dead/Cancelled
    BEECHAM INC.
    1973-06-27

    © 2023 FDA.report
    This site is not affiliated with or endorsed by the FDA.